Lupin Limited has informed the Exchange regarding a press release dated February 23, 2026, titled "Lupin Receives European Commission Approval for Biosimilar Ranibizumab".
Lupin Limited has informed the Exchange regarding a press release dated February 23, 2026, titled "Lupin Receives European Commission Approval for Biosimilar Ranibizumab".